Influenza treatments
Explore information about Influenza. An independent doctor decides whether a prescription is appropriate. Dispensing and delivery depend on a valid prescription, the available route and an independent licensed pharmacy.
Choose a treatment to review
Pricing is indicative where shown. Final route, fulfilment, and whether treatment is clinically appropriate remain subject to independent doctor review. Check platform, independent doctor, pharmacy and delivery charges before payment. A listed medicine amount is not a complete route quotation.
Relenza (Zanamivir)
Relenza inhaled antiviral: Spanish treatment and prevention timing, Diskhaler dosing, milk-protein allergy and bronchospasm warnings.
Tamiflu (Oseltamivir)
Tamiflu for influenza: Spanish product information, treatment versus prevention, 6 mg/mL suspension, renal precautions and limits of the evidence.
About influenza treatments
Influenza is a highly contagious acute respiratory infection caused by influenza A and B viruses. It represents a significant annual public health challenge across Europe, with seasonal epidemics causing millions of illness episodes and thousands of deaths each year. The European Centre for Disease Prevention and Control (ECDC) estimates that influenza is responsible for approximately 40,000 excess deaths per year in the EU, the vast majority occurring in vulnerable and elderly populations.
Most healthy adults with influenza experience a self-limiting illness characterised by sudden onset of fever, myalgia (muscle aches), headache, dry cough, sore throat, and fatigue. Symptoms typically resolve within 5–8 days, though fatigue and cough may persist longer. The high contagiousness of influenza — spread via respiratory droplets and contact with contaminated surfaces — means that seasonal epidemics can propagate rapidly through communities.
For healthy adults with uncomplicated influenza, symptomatic management with rest, adequate fluid intake, and over-the-counter analgesics and antipyretics is often sufficient. However, for patients in high-risk groups or those presenting with more severe illness, antiviral medications can significantly reduce the duration and severity of symptoms, lower the risk of complications such as secondary bacterial pneumonia, and decrease the risk of hospitalisation.
Antiviral medications work by interfering with the replication or spread of the influenza virus. They do not treat bacterial infections and are not effective against the common cold or other respiratory viruses. Their benefit is critically time-dependent — treatment is most effective when initiated within 48 hours of symptom onset — which is why rapid access to medical assessment is clinically valuable.
Available treatments
The following antiviral medications for influenza are described here. Independent doctors make prescribing decisions. Licensed pharmacies dispense only where approved and available. This comparison is provided for informational purposes only.
| Medication | Active Ingredient | Class | Administration | Course Duration |
|---|---|---|---|---|
| Oseltamivir (Tamiflu) | Oseltamivir phosphate | Neuraminidase inhibitor | Oral capsule | 5 days |
| Zanamivir | Zanamivir | Neuraminidase inhibitor | Inhaled powder | 5 days |
| Baloxavir (Xofluza) | Baloxavir marboxil | Cap-dependent endonuclease inhibitor | Oral tablet | Single dose |
Key distinctions:
- Oseltamivir (Tamiflu): The most widely prescribed influenza antiviral in Europe. Oral administration and good tolerability make it practical for outpatient use. A paediatric liquid suspension is also available. Generic oseltamivir is available in many EU countries.
- Zanamivir: Administered via inhalation using a Diskhaler device. An alternative for patients who cannot tolerate oral oseltamivir, but not suitable for patients with underlying respiratory conditions such as asthma or COPD due to risk of bronchospasm.
- Baloxavir (Xofluza): A newer antiviral with a novel mechanism, taken as a single oral dose. Approved by the EMA. May be preferred by patients for whom a full 5-day course represents an adherence challenge. Clinical data show comparable efficacy to oseltamivir for uncomplicated influenza.
How to get influenza treatment online
Prescrivia operates as a technology intermediary. We do not prescribe medications, employ doctors, or sell medicines. Our platform collects your health assessment for review by an independent licensed prescriber.
The process:
-
Complete a health assessment — Answer a structured set of medical questions covering your symptoms, time of onset, medical history (particularly high-risk conditions), current medications, and any known exposure history. Speed of assessment is important given the 48-hour treatment window.
-
Independent doctor review — An independent doctor reviews your assessment. If antiviral treatment is clinically appropriate based on your risk profile and symptom timing, the doctor may issue a prescription. If your symptoms suggest a different diagnosis or require urgent in-person care, the doctor will advise accordingly.
-
Pharmacy fulfilment — A valid prescription does not guarantee dispensing or delivery. An independent licensed pharmacy checks lawful supply, stock and an available supply route for the destination country.
Important: Prescrivia does not guarantee that a prescription will be issued. Prescribing decisions are made entirely by independent medical professionals. Given the time-sensitive nature of antiviral treatment, same-day or next-day delivery options may be relevant — check availability in your country at checkout.
How we compare
| Through Prescrivia | In-person GP appointment | |
|---|---|---|
| Availability | Online assessment, subject to platform availability | Subject to appointment availability |
| Wait time | Review time depends on clinical needs and availability | Depends on appointment availability |
| Travel required | No — reduces risk of spreading illness | Yes |
| Prescribing decision | Made by independent doctor | Made by your GP |
| Time-sensitivity | 48-hour window; timely assessment and delivery are not guaranteed | Depends on appointment availability |
| Cost | Transparent pricing displayed upfront | Varies by country and healthcare system |
Note: Influenza presenting with difficulty breathing, chest pain, confusion, severe or persistent vomiting, or symptoms of deterioration after initial improvement warrants immediate in-person emergency evaluation. Online assessment is appropriate for adults with uncomplicated influenza symptoms whose condition is stable and who can safely await assessment and delivery.
Sources
Medical information on this page is based on the following sources:
- European Medicines Agency (EMA). Tamiflu (oseltamivir) — Summary of Product Characteristics. Available at: ema.europa.eu
- European Centre for Disease Prevention and Control (ECDC). Influenza — annual epidemiological report. ecdc.europa.eu
- World Health Organization (WHO). Influenza (seasonal) — Key facts. who.int
Medical information may change as clinical guidance is updated. It is provided for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for advice relevant to your individual health circumstances.
Availability, dispensing and delivery depend on the country, clinical assessment, pharmacy and applicable law. A Spanish-language page does not establish eligibility for supply in Spain.
Frequently asked questions
- How does an online assessment for antiviral medication for influenza work?
- Yes. Through Prescrivia, you can complete a health assessment reviewed by an independent doctor. Where antiviral treatment is clinically appropriate — based on your symptoms, timing, and risk profile — the doctor may issue a prescription. A pharmacy may dispense after confirming a valid prescription, applicable requirements, stock and availability for the destination. Dispensing and delivery are not guaranteed.
- How quickly do antiviral medications need to be taken to be effective?
- Antiviral medications for influenza are most effective when started within 48 hours of symptom onset. After this window, clinical benefit is significantly reduced, though treatment may still be considered for high-risk patients with severe illness or those who are deteriorating. Rapid access to online assessment can help patients begin treatment within the critical window.
- Who is most at risk from influenza complications?
- High-risk groups include adults aged 65 and over, pregnant women, individuals with chronic cardiovascular or respiratory conditions (including asthma and COPD), those with diabetes or immunosuppression, and residents of care facilities. These groups may benefit most from early antiviral treatment and should also consider annual influenza vaccination.
- Is antiviral medication the same as the influenza vaccine?
- No. Antiviral medications such as oseltamivir (Tamiflu) treat active influenza infection or may be used for post-exposure prophylaxis. They are not a substitute for vaccination, which remains the primary tool for influenza prevention. If you have influenza symptoms and are in a high-risk group, seeking antiviral treatment promptly is still recommended even if you have been vaccinated.
- What is the difference between oseltamivir and baloxavir?
- Oseltamivir (Tamiflu) and zanamivir are neuraminidase inhibitors that prevent the influenza virus from spreading between cells. Baloxavir is a cap-dependent endonuclease inhibitor — a newer mechanism that disrupts viral RNA replication. Baloxavir is taken as a single dose rather than a 5-day course, which may improve adherence.
Intermediary notice: Prescrivia connects patients with independent doctors and licensed pharmacies. We do not provide medical advice, employ doctors, or sell medicines. All medical decisions are made by independent healthcare professionals, and prescription-only medicines require a valid prescription. Treatment is not guaranteed — whether a prescription is issued depends on an independent doctor's clinical assessment.
Ready to begin your assessment?
Complete a short health assessment and, where clinically appropriate, connect with an independent doctor for review.
Prescrivia is not a doctor or pharmacy — it is a technology platform. Any prescription decision is made by an independent doctor; medicines are dispensed by licensed pharmacies only where available.